Evolution of induction chemotherapy for non-small cell lung cancer over the last 30 years: A surgical appraisal

摘要: Background Induction chemotherapy (ICT) is supposed to reduce the risk of micrometastatic progression and improve resectability non-small cell lung cancer (NSCLC). However, best indications for ICT strategy remain unclear in published meta-analyses. Based on this observation, an evaluation daily practice importance. Therefore, we reviewed efficacy time trends our 30-year series. Methods A database including all patients with NSCLC who underwent surgical resection two French centers from 1980 2009 (n = 5563) was prospectively set retrospectively reviewed. The indications, clinical pathologic response rates, overall survival 732) were analyzed during three successive time-periods: P1 1989, P2 1990 1999, P3 2000 2009. Results The proportion benefited increased over time, 2.8% 35) 12.5% 274) P2, 20.2% 423) P3. Indications evolved more N2 211; 49.8%) less initially unresectable 72; 17%) rate between increased. Five 10-year rates 35.2% 21.5%, respectively. In multivariate analysis, time-period, age, type resection, histology, significant prognostic factors. Conclusions Our report off-trial use induction therapy last 30 years demonstrates ICT, a progressive focus disease, improved rates.